Estradiol promotes rapid degradation of HER3 in ER-positive breast cancer cell line MCF-7

被引:5
|
作者
Suga, Junko [1 ]
Izumiyama, Keiko [2 ]
Tanaka, Nobuyuki [2 ,3 ]
Saji, Shigehira [1 ]
机构
[1] Fukushima Med Univ, Dept Med Oncol, 1 Hikariga Oka, Fukushima, Fukushima 9601295, Japan
[2] Miyagi Canc Ctr Res Inst, Div Canc Biol & Therapeut, 47-1 Nodayama, Natori, Miyagi 9811293, Japan
[3] Tohoku Univ, Dept Canc Med Sci, Div Canc Immunobiol, Grad Sch Med,Aoba Ku, 2-1 Seiryo, Sendai, Miyagi 9800875, Japan
关键词
HER3; Nedd4-1; Estradiol; ER; Degradation;
D O I
10.1016/j.bbrep.2018.10.008
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
HER3, a member of the receptor tyrosine kinase super family, is overexpressed in a number of cancers, and is associated with malignant phenotypes. Control of the protein stability of the membrane, as well as nuclear receptors, has been known to be an important process affecting tumor cells; however, their relationships have yet to be elucidated. In this study, we demonstrate that estradiol promotes rapid degradation of HER3 via the proteasome pathway in ER-positive breast cancer, MCF-7. ER prevented HER3 degradation, and knockdown of ER expression by si-RNA promoted rapid degradation of HER3. Breakdown of HER3 and ER were regulated by a ubiquitin ligase Nedd4-1 in the presence of estradiol stimulation. We speculate that estradiol quickly degrades ER, making HER3 accessible by Nedd4-1, and leads to the rapid degradation of HER3. In addition, knockdown of ubiquitin ligase Nedd4-1 enhances estradiol induced cell proliferation. These results indicate that HER3 and Nedd4-1 in ER-positive breast cancers might be an important therapeutic target.
引用
收藏
页码:103 / 109
页数:7
相关论文
共 50 条
  • [31] The effects of β-estradiol on Raf activity, cell cycle progression and growth factor synthesis in the MCF-7 breast cancer cell line
    Weinstein-Oppenheimer, CR
    Burrows, A
    Steelman, LS
    McCubrey, JA
    [J]. CANCER BIOLOGY & THERAPY, 2002, 1 (03) : 256 - 262
  • [32] Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib
    Chen, Chen
    Shen, Hui Ling
    Yang, Jing
    Chen, Qiao Yun
    Xu, Wen Lin
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2011, 137 (01) : 9 - 17
  • [33] MCF-7: The first hormone-responsive breast cancer cell line
    Levenson, AS
    Jordan, VC
    [J]. CANCER RESEARCH, 1997, 57 (15) : 3071 - 3078
  • [34] Mathematical modeling of tumor growth: the MCF-7 breast cancer cell line
    Wei, Hsiu-Chuan
    [J]. MATHEMATICAL BIOSCIENCES AND ENGINEERING, 2019, 16 (06) : 6512 - 6535
  • [35] HETEROGENEITY OF THE HUMAN-BREAST CANCER CELL-LINE MCF-7
    BUTLER, B
    BERLINSKI, PJ
    KELSEY, WH
    TOENNIGES, MM
    [J]. PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1982, 23 (MAR): : 236 - 236
  • [36] Proteomic analysis of MCF-7 breast cancer cell line exposed to leptin
    Valle, A.
    Sastre-Serra, J.
    Pol, C.
    Miro, A. M.
    Oliver, J.
    Roca, P.
    [J]. ANALYTICAL CELLULAR PATHOLOGY, 2011, 34 (03) : 147 - 157
  • [37] Identification of DNA palindromes in the MCF-7 breast cancer cell line.
    Yang, Hui
    Volfovsky, Natalia
    Rattray, Alison
    Chen, Xiongfong
    Tanaka, Hisashi
    Jeffrey, Strathern
    [J]. CANCER RESEARCH, 2013, 73 (08)
  • [38] Preventing chemoresistance of human breast cancer cell line, MCF-7 with celecoxib
    Chen Chen
    Hui Ling Shen
    Jing Yang
    Qiao Yun Chen
    Wen Lin Xu
    [J]. Journal of Cancer Research and Clinical Oncology, 2011, 137 : 9 - 17
  • [39] Vitamin D - Metabolism in the human breast cancer cell line MCF-7
    Diesing, Dagmar
    Cordes, Tim
    Fischer, Dorothea
    Diedrich, Klaus
    Friedrich, Michael
    [J]. ANTICANCER RESEARCH, 2006, 26 (4A) : 2755 - 2759
  • [40] Multiparametric flow cytometric analysis in a breast cancer cell line (MCF-7)
    Lee, GSR
    Ryu, KS
    Rha, JG
    Kim, SP
    Namkoong, SE
    Han, KT
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2002, 28 (03) : 141 - 148